Lumbard & Kellner LLC Invests $3.30 Million in Zoetis Inc (ZTS) Stock
Lumbard & Kellner LLC bought a new stake in Zoetis Inc (NYSE:ZTS) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 51,820 shares of the company’s stock, valued at approximately $3,304,000. Zoetis accounts for 1.8% of Lumbard & Kellner LLC’s investment portfolio, making the stock its 23rd biggest position.
A number of other large investors have also bought and sold shares of the business. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Zoetis by 16.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after buying an additional 230 shares during the period. Harfst & Associates Inc. raised its holdings in shares of Zoetis by 16.1% in the 2nd quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock valued at $117,000 after buying an additional 260 shares during the period. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its holdings in shares of Zoetis by 251.9% in the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after buying an additional 1,360 shares during the period. Almanack Investment Partners LLC. purchased a new stake in shares of Zoetis in the 2nd quarter valued at $119,000. Finally, Peddock Capital Advisors LLC purchased a new stake in shares of Zoetis in the 2nd quarter valued at $140,000. Institutional investors own 93.33% of the company’s stock.
Several equities research analysts recently issued reports on the company. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price objective on the stock in a report on Thursday, October 12th. Cantor Fitzgerald reiterated a “buy” rating and issued a $75.00 price objective on shares of Zoetis in a report on Wednesday, September 6th. BidaskClub downgraded Zoetis from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Morgan Stanley boosted their price objective on Zoetis from $61.00 to $70.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. Finally, Piper Jaffray Companies set a $73.00 price objective on Zoetis and gave the company a “buy” rating in a report on Friday, August 25th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $68.53.
Zoetis Inc (NYSE ZTS) traded down $0.11 on Tuesday, reaching $71.77. The company had a trading volume of 1,172,500 shares, compared to its average volume of 2,760,692. Zoetis Inc has a 1 year low of $50.57 and a 1 year high of $72.79. The firm has a market cap of $35,026.28, a PE ratio of 32.97, a price-to-earnings-growth ratio of 2.15 and a beta of 1.06. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95.
Zoetis (NYSE:ZTS) last released its earnings results on Thursday, November 2nd. The company reported $0.65 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.02. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The firm had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.32 billion. During the same period in the previous year, the firm posted $0.52 EPS. Zoetis’s revenue for the quarter was up 8.5% on a year-over-year basis. equities research analysts anticipate that Zoetis Inc will post 2.37 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Thursday, November 9th were given a dividend of $0.105 per share. The ex-dividend date was Wednesday, November 8th. This represents a $0.42 annualized dividend and a dividend yield of 0.59%. Zoetis’s dividend payout ratio is currently 22.11%.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with Analyst Ratings Network's FREE daily email newsletter.